Both are GLP-1 drugs that mimic the natural hormone in your body that regulates appetite. Wegovy has the active ingredient semaglutide that is administered weekly, and could help you lose ~20% of your weight. Saxenda has the active ingredient liraglutide that is administered daily, and could help you lose ~10% of your weight. Individual results may vary. Weight loss depends on adherence to treatment and lifestyle modifications.

Adults 18+ with a BMI of ≥ 27.5 (or ≥ 23 with certain health risks). Doctor confirmation is required.

Gradual dose taper + ongoing nutrition and exercise lowers rebound risk.

Adequate protein intake and resistance exercise helps preserve lean muscle mass.

Common side effects include nausea, diarrhoea, constipation, vomiting, injection site reactions, and low blood sugar. More serious side effects may occur and should be discussed with your doctor.

• Thyroid tumors have been noted in rodent studies with semaglutide and liraglutide (not all GLP-1s necessarily), so Wegovy and Saxenda should not be used in patients with a personal or family history of MTC or MEN 2.
• Pancreatitis has been reported in patients taking Wegovy and Saxenda. Treatment should be discontinued if pancreatitis is suspected.
• Wegovy and Saxenda may cause hypoglycemia in patients with type 2 diabetes on anti-diabetic therapy.

• Personal or family history of medullary thyroid carcinoma (MTC).
• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pregnancy, as weight loss offers no potential benefit during this time and can harm an unborn baby.
• Allergic reactions to semaglutide (Wegovy), liraglutide (Saxenda), or any other components of these medications.